Investor Relations
Corporate Profile
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGelTM, a reverse-thermal sustained-release, hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.
UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Events
Mar 14, 2024 at 10:00 AM EDT
Mar 4, 2024 at 1:30 PM EST
Feb 13, 2024 at 12:00 PM EST
Press Releases
Apr 17, 2024
Apr 15, 2024
Apr 03, 2024
Annual Reports
Proxy Materials